Eli Lilly and Company (LLY) Stock Forecast & Price Target

$974.82 -12.23 (-1.24%)

Closing price 03:59 PM Eastern

Extended Trading

$971.68 -3.15 (-0.32%)

As of 07:59 PM Eastern

Compare

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 30 Analyst Ratings

Sell
1

Hold
4

Buy
25

Based on 30 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 30 analysts, 1 has given a sell rating, 4 have given a hold rating, 23 have given a buy rating, and 2 have given a strong buy rating for LLY.

Consensus Price Target

$1,217.59
24.90% Upside

According to the 30 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $1,217.59. The highest price target for LLY is $1,400.00, while the lowest price target for LLY is $850.00. The average price target represents a forecasted upside of 24.90% from the current price of $974.82.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LLY Analyst Ratings Over Time

Type	Current Forecast 5/7/25 to 5/7/26	1 Month Ago 4/7/25 to 4/7/26	3 Months Ago 2/6/25 to 2/6/26	1 Year Ago 5/7/24 to 5/7/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	23 Buy rating(s)	23 Buy rating(s)	19 Buy rating(s)	18 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$1,217.59	$1,222.22	$1,203.75	$1,002.80
Forecasted Upside	24.90% Upside	31.41% Upside	13.87% Upside	29.07% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Eli Lilly and Company Stock vs. The Competition

Type	Eli Lilly and Company	Medical Companies	S&P 500
Consensus Rating Score	2.87	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	24.64% Upside	876.08% Upside	14.95% Upside
News Sentiment Rating	Positive News See Recent LLY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/5/2026	Guggenheim 5 of 5 stars	Seamus Fernandez 5 of 5 stars	Reiterated Rating	Buy	$1,183.00	+22.27%
5/4/2026	Weiss Ratings Not Rated		Upgrade	Buy (B-) ➝ Buy (B)
5/4/2026	Wolfe Research 4 of 5 stars	Alexandria Hammond Not Rated	Reiterated Rating	Outperform	$1,325.00	+37.20%
5/4/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,350.00 ➝ $1,400.00	+44.62%
5/1/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$1,344.00	+39.79%
5/1/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
5/1/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Gerberry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,294.00 ➝ $1,133.00	+17.39%
5/1/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,205.00 ➝ $1,230.00	+26.73%
5/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$1,260.00 ➝ $1,283.00	+32.19%
4/27/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$1,296.00 ➝ $1,058.00	+19.76%
Get the Latest News and Ratings for LLY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.
4/10/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$875.00 ➝ $880.00	-8.06%
3/18/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
3/17/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Hold ➝ Reduce	$1,070.00 ➝ $850.00	-13.95%
3/13/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$1,300.00	+30.15%
3/10/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Courtney Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
3/6/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Shin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$1,285.00	+30.49%
2/23/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robyn Karnauskas Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
2/19/2026	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$950.00 ➝ $1,050.00	+2.71%
2/18/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Narumi Nakagiri Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,230.00 ➝ $1,250.00	+22.24%
2/11/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$1,060.00 ➝ $1,107.00	+5.53%
2/10/2026	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ilya Zubkov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$1,200.00	+17.07%
2/10/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
2/9/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$930.00 ➝ $1,200.00	+14.40%
2/5/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$1,300.00	+26.01%
2/5/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,200.00 ➝ $1,280.00	+15.61%
2/5/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$1,300.00	+17.42%
2/5/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,150.00 ➝ $1,300.00	+25.57%
1/30/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
1/29/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$960.00 ➝ $1,250.00	+20.59%
12/1/2025	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$1,286.00	+21.58%
10/14/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
8/14/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
1/28/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,250.00 ➝ $1,190.00	+47.25%
9/5/2024	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:48 PM ET.

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 4, 2026. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

The company has demonstrated significant revenue growth, with a recent quarterly revenue increase of over 55% compared to the same period last year, indicating strong market demand for its products.
Eli Lilly and Co has set ambitious earnings per share (EPS) guidance for FY 2026, projecting between 35.500 and 37.000 EPS, which suggests confidence in future profitability.
Recent analyst upgrades have raised the price target for Eli Lilly and Co shares, with estimates now reaching around $1,283, reflecting positive sentiment and potential for stock appreciation.
The company has a strong portfolio of innovative therapies, positioning it well in the competitive pharmaceutical market, which can lead to sustained revenue streams.
With a consensus rating of "Moderate Buy" from analysts, the stock is viewed favorably, suggesting that many experts believe it is a good investment opportunity.

Eli Lilly and Company
Bear Case

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

Despite the positive growth, there is a risk of market volatility that could impact stock performance, especially in the pharmaceutical sector where regulatory changes can affect operations.
One analyst has issued a "Sell" rating, indicating that not all market experts are confident in the stock's future performance, which could lead to potential declines.
Competition in the pharmaceutical industry is fierce, and new entrants could challenge Eli Lilly and Co's market share, potentially affecting future revenue growth.
While the company has strong earnings projections, any failure to meet these expectations could lead to negative investor sentiment and a decline in stock price.
Investors should be cautious of the overall economic environment, as broader economic factors can influence healthcare spending and, consequently, Eli Lilly and Co's performance.

LLY Forecast - Frequently Asked Questions

: According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $1,217.59, with a high forecast of $1,400.00 and a low forecast of $850.00.
: 30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There is currently 1 sell rating, 4 hold ratings, 23 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares.
: According to analysts, Eli Lilly and Company's stock has a predicted upside of 24.90% based on their 12-month stock forecasts.
: Over the previous 90 days, Eli Lilly and Company's stock had 2 upgrades and 1 downgrade by analysts.
: Eli Lilly and Company has been rated by research analysts at Argus, Bank of America, Barclays, Berenberg Bank, Cantor Fitzgerald, CICC Research, Daiwa Securities Group, Deutsche Bank Aktiengesellschaft, Freedom Capital, Guggenheim, HSBC, Jefferies Financial Group, Leerink Partners, Loop Capital, Morgan Stanley, Rothschild & Co Redburn, Royal Bank Of Canada, Sanford C. Bernstein, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, and Wolfe Research in the past 90 days.
: Analysts like Eli Lilly and Company more than other "medical" companies. The consensus rating for Eli Lilly and Company is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how LLY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Eli Lilly and Company Recommendations

This page (NYSE:LLY) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Stock Forecast & Price Target

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

LLY Analyst Ratings Over Time

LLY Analyst Recommendations By Month

LLY Price Targets by Month

Eli Lilly and Company Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

Eli Lilly and Company
Bull Case

Eli Lilly and Company
Bear Case

LLY Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Eli Lilly and Company Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eli Lilly and Company (LLY) Stock Forecast & Price Target

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

LLY Analyst Ratings Over Time

LLY Analyst Recommendations By Month

LLY Price Targets by Month

Eli Lilly and Company Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

Eli Lilly and Company Bull Case

Eli Lilly and Company Bear Case

LLY Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Eli Lilly and Company Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Eli Lilly and Company
Bull Case

Eli Lilly and Company
Bear Case